文献速递肾癌与肾肿瘤

立体定向放疗作为孤立肾肾肿瘤的治疗选择:IROCK多中心分析

Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
PubMed 文献 · J Urol · 2019-01-01

该多中心分析汇总9家IROCK机构数据,评估孤立肾患者接受立体定向消融放疗的肿瘤学和肾功能结局。孤立肾组81例,中位随访2.6年,2年局部控制率98.0%、无进展生存率77.5%、肿瘤特异性生存率98.2%、总生存率81.5%,无患者需透析,肾功能与肿瘤学结局与双侧肾组无显著差异。

要点

  • 孤立肾组81例接受立体定向消融放疗,中位随访2.6年,无患者需透析。
  • 2年局部控制率98.0%、无进展生存率77.5%、肿瘤特异性生存率98.2%、总生存率81.5%。
  • 肿瘤≥4 cm与eGFR下降≥15 ml/min相关(OR 4.2,p=0.029)。

核心结论

  • 在IROCK数据库分析中,孤立肾患者接受立体定向消融放疗对肾功能影响可接受,肿瘤学结局优异,与双侧肾患者相似。
  • 因此立体定向消融放疗是孤立肾肾细胞癌患者可行的治疗选择。

研究设计与样本

  • 汇总来自德国、澳大利亚、美国、加拿大和日本9家IROCK机构的个体患者数据。
  • 比较孤立肾队列与双侧肾队列的基线特征和结局,采用逻辑回归评估放疗后肾功能预测因素。
  • 孤立肾组81例,双侧肾组138例,中位随访2.6年。

主要发现

  • 孤立肾组平均年龄67.3岁,97.5%患者体能状态良好(ECOG 0-1或KPS≥70%)。
  • 孤立肾组中位肿瘤直径3.7 cm(IQR 2.5-4.3),37%肿瘤≥4 cm。
  • 双侧肾组肿瘤更大、年龄更大(p<0.001),基线eGFR更低(p=0.024)。
  • 孤立肾组放疗后eGFR平均下降-5.8±10.8 ml/min(-9%),无患者需透析。
  • 孤立肾组肿瘤≥4 cm与eGFR下降≥15 ml/min相关(OR 4.2,p=0.029)。

临床怎么用

  • 原文结论认为立体定向消融放疗是孤立肾肾细胞癌患者可行的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic ablative radiotherapy is an emerging treatment for renal cell carcinoma. Our study objective was to evaluate this therapy in patients with a solitary kidney, focusing on oncologic and renal function outcomes. MATERIALS AND METHODS: We pooled individual patient data from 9 IROCK (International Radiosurgery Oncology Consortium for Kidney) institutions in Germany, Australia, the United States of America, Canada and Japan. Median followup was 2.6 years. Baseline characteristics and outcomes were compared between the solitary and bilateral kidney cohorts. Predictors of renal function after stereotactic ablative radiotherapy were assessed by logistic regression modeling. RESULTS: A total of 81 patients with a solitary kidney underwent stereotactic ablative radiotherapy. Mean age was 67.3 years and 97.5% of patients had good performance status, including ECOG (Eastern Cooperative Oncology Group) 0-1 or KPS (Karnofsky Performance Status) 70% or greater. Median tumor diameter was 3.7 cm (IQR 2.5-4.3) and 37% of tumors were 4 cm or greater. The 138 patients in the bilateral cohort harbored larger tumors and were older (p <0.001) with a lower baseline estimated glomerular filtration rate (p = 0.024). After stereotactic ablative radiotherapy in the solitary kidney cohort the mean ± SD estimated glomerular filtration rate decrease was -5.8 ± 10.8 ml per minute (-9%). No patient with a solitary kidney required dialysis. After stereotactic ablative radiotherapy a tumor size of 4 cm or greater was associated with an estimated glomerular filtration rate decrease of 15 ml per minute or greater (OR 4.2, p = 0.029). At 2 years the rates of local control, and progression-free, cancer specific and overall survival in the solitary cohort were 98.0%, 77.5%, 98.2% and 81.5%, respectively. There was no significant difference in renal function or oncologic outcomes between the cohorts (p >0.05). CONCLUSIONS: In this analysis of the IROCK database stereotactic ablative radiotherapy in patients with a solitary kidney had an acceptable impact on renal function and achieved excellent oncologic outcomes, similar to those in patients with bilateral kidneys. Thus, stereotactic ablative radiotherapy represents a viable treatment option in patients with renal cell carcinoma in a solitary kidney.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Correa RJM, Louie AV, Staehler M, et al. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. J Urol. 2019. PMID: 30741849. doi:10.1097/JU.0000000000000111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。